Modulus Therapeutics
Business Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2101 N 34th St Ste 195, Seattle, Washing...Phone Number
(801) 534-7260Website
www.modulustherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Modulus Therapeutics
Modulus Therapeutics is focused on mainstreaming cell therapies for autoimmune diseases through innovative approaches in rapid prototyping and generative design. The company aims to overcome the limitations of current CAR-T treatments by developing off-the-shelf CAR-NK therapies that are safer and more accessible to patients. With a platform for crafting custom CARs and switch receptors, Modulus enhances the efficacy of immune cell therapies while reducing the preparation burdens typically associated with such treatments. Their clientele primarily includes autoimmune patients seeking more effective and accessible cell therapy options.Explore more
Modulus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Modulus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Modulus Therapeutics is spiking on competitors!
Check if Modulus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Modulus Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Modulus Therapeutics
Product Launch: Get notified when Modulus Therapeutics launches new products
Earning: See what the market has to say on Modulus Therapeutics recently announced quarterly report
Modulus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Modulus Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Modulus Therapeutics
Find 2 more new buyers
Compare Similar Companies to Modulus Therapeutics
Compare insights from companies similar to Modulus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Modulus Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Modulus Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Modulus Therapeutics.
Modulus Therapeutics financials insights
Gather financial insights about Modulus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$3.5M
Modulus Therapeutics Tech Stack
A closer look at the technologies used by Modulus Therapeutics
Modulus Therapeutics News & Media
Ginkgo loads up Modulus CAR assets, latest in a string of deals - Fierce Biotech
Ginkgo Bioworks’ swift moving business development team is slowing down long enough to load up some new chimeric antigen receptor (CAR) assets from Modulus Therapeutics. | Ginkgo Bioworks’ swift moving business development team is slowing down long enough to load up some new chimeric antigen receptor (CAR) assets from Modulus Therapeutics.Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and...Modulus Therapeutics Secures $3.5 Million in Seed Funding Round
Modulus Therapeutics raises $3.5 million in seed funding round that was oversubscribed.Modulus Therapeutics Secures Funding for Cell Therapy Design Platform, Adds Alana Welm and ...
Modulus Therapeutics Utilizes Gene Editing and Machine Learning to Converge on Optimized Immune Cell Therapies
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Modulus Therapeutics
Sign Up For FreeTo access detailed company insights
Modulus Therapeutics is focused on mainstreaming cell therapies for autoimmune diseases through innovative approaches in rapid prototyping and generative design. The company aims to overcome the limitations of current CAR-T treatments by developing off-the-shelf CAR-NK therapies that are safer and more accessible to patients. With a platform for cr... Read More
